Suppr超能文献

宫颈发育不良患者中 VEGF +936 C/T 基因多态性。

VEGF +936 C/T Genetic Polymorphism in Patients with Cervical Dysplasia.

机构信息

1st Clinic of Obstetrics and Gynecology, University of Medicine and Pharmacy "Iuliu Hatieganu", Clinicilor 3-5, 400006 Cluj-Napoca, Romania.

Department of Economic Sciences, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, Calea Manastur 3-5, 400372 Cluj-Napoca, Romania.

出版信息

Anal Cell Pathol (Amst). 2016;2016:6074275. doi: 10.1155/2016/6074275. Epub 2016 Oct 12.

Abstract

. The present study aims to analyze the potential role of VEGF +936 C/T polymorphism in cervical intraepithelial neoplasia. . One hundred and eighty-six patients were included in the study: 75 cases (patients diagnosed with CIN) and 111 controls (negative for both HPV testing and cytology). For each patient a single visit was scheduled when colposcopy was performed. From cervical specimen, cytology and HPV testing were performed and from peripheral blood VEGF +936 genotyping was determined. For statistical analysis purposes OR and chi-square were used at a level of significance of <0.05. . No link has been found in the detection of CT genotype in cases versus controls, OR = 0.8295, [0.42, 1.62]. An inverse correlation has been found between T allele and HSIL, OR = 0.2121, [0.0473, 0.9517], = 0.0866. . No link has been found between VEGF +936 C/T and cervical intraepithelial neoplasia.

摘要

. 本研究旨在分析 VEGF +936 C/T 多态性在子宫颈上皮内瘤变中的潜在作用。. 研究共纳入 186 例患者:75 例(诊断为 CIN 的患者)和 111 例对照(HPV 检测和细胞学均为阴性)。每位患者在进行阴道镜检查时安排单次就诊。从宫颈标本中进行细胞学和 HPV 检测,并从外周血中确定 VEGF +936 基因分型。为了进行统计分析,采用 OR 和卡方检验,显著性水平为 <0.05。. 在病例与对照组中未发现 CT 基因型的检出存在关联,OR = 0.8295,[0.42,1.62]。T 等位基因与 HSIL 呈负相关,OR = 0.2121,[0.0473,0.9517],= 0.0866。. 在 VEGF +936 C/T 与子宫颈上皮内瘤变之间未发现关联。

相似文献

1
VEGF +936 C/T Genetic Polymorphism in Patients with Cervical Dysplasia.
Anal Cell Pathol (Amst). 2016;2016:6074275. doi: 10.1155/2016/6074275. Epub 2016 Oct 12.
2
Vascular endothelial growth factor gene polymorphisms and risk of cervical intraepithelial neoplasia.
Int J Gynecol Cancer. 2011 May;21(4):597-601. doi: 10.1097/IGC.0b013e318214557c.

本文引用的文献

1
Natural history of high-grade cervical intraepithelial neoplasia: a review of prognostic biomarkers.
Expert Rev Mol Diagn. 2015 Apr;15(4):527-46. doi: 10.1586/14737159.2015.1012068. Epub 2015 Feb 21.
3
Angiogenesis and antiangiogenic agents in cervical cancer.
Onco Targets Ther. 2014 Dec 3;7:2237-48. doi: 10.2147/OTT.S68286. eCollection 2014.
4
Influence of serum VEGF levels on therapeutic outcome and diagnosis/prognostic value in patients with cervical cancer.
Asian Pac J Cancer Prev. 2014;15(20):8793-6. doi: 10.7314/apjcp.2014.15.20.8793.
5
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
8
VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival.
Gynecol Oncol. 2010 Nov;119(2):232-6. doi: 10.1016/j.ygyno.2010.07.035. Epub 2010 Aug 24.
9
Anti-angiogenesis agents in metastatic or recurrent cervical cancer.
Gynecol Oncol. 2010 Feb;116(2):181-6. doi: 10.1016/j.ygyno.2009.09.033. Epub 2009 Oct 27.
10
Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
Expert Rev Anticancer Ther. 2009 Jul;9(7):895-903. doi: 10.1586/era.09.58.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验